Literature DB >> 21099280

CXCL10- a path to β-cell death.

Federico Paroni1, Erna Domsgen, Kathrin Maedler.   

Abstract

The ability of the β-cells to control blood glucose levels depends on their function and mass. In both, type 1 and type 2 diabetes mellitus the main processes leading to β-cell failure are apoptosis and loss of function. Many studies demonstrate how cytokines and chemokines have an active role in triggering the immune-response against the β-cell population. In a recent study we have identified that the chemokine CXCL10 may play an active role in triggering β-cell destruction.  We have identified the Toll like receptor 4 as the receptor for CXCL10 and as new pathway for the induction of β-cell apoptosis. Our findings may open new therapeutic approaches to fight onset and progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 21099280     DOI: 10.4161/isl.1.3.9110

Source DB:  PubMed          Journal:  Islets        ISSN: 1938-2014            Impact factor:   2.694


  3 in total

1.  Toll-Like Receptor 3 Is Critical to the Pancreatic Islet Milieu That Is Required for Coxsackievirus B4-Induced Type 1 Diabetes in Female Nonobese Diabetic Mice.

Authors:  Sarah E Benner; Debra L Walter; Jean R Thuma; Maria Courreges; Calvin B L James; Frank L Schwartz; Kelly D McCall
Journal:  Pancreas       Date:  2022-01-01       Impact factor: 3.243

2.  Relationship between cytokine release and stress hyperglycemia in patients hospitalized with COVID-19 infection.

Authors:  Andrea Da Porto; Carlo Tascini; Gianluca Colussi; Maddalena Peghin; Elena Graziano; Chiara De Carlo; Luca Bulfone; Martina Antonello; Emanuela Sozio; Martina Fabris; Francesco Curcio; Carlo Pucillo; Cristiana Catena; Leonardo A Sechi
Journal:  Front Med (Lausanne)       Date:  2022-08-19

Review 3.  Diabetes and beta cell function: from mechanisms to evaluation and clinical implications.

Authors:  Simona Cernea; Minodora Dobreanu
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.